An Investigational Study to Evaluate Experimental Medication SYHX1901 Tablets With Moderate to Severe Plaque Psoriasis

A Randomized, Double-blind, Placebo-controlled Phase Ⅱ Study to Evaluate the Efficacy and Safety of SYHX1901 Tablets in the Treatment of Moderate to Severe Plaque Psoriasis

The purpose of this study is to evaluate the efficacy and safety of different doses of SYHX1901 tablets in the treatment of moderate to severe plaque psoriasis in order to select doses for further clinical trials.

Study Overview

• Status: Completed
• Conditions: Effects, Drug Side
• Intervention / Treatment: Drug: Placebo; Drug: SYHX1901

Detailed Description

This is a multicenter, randomized, double-blind, placebo-controlled phase Ⅱ study to evaluate the efficacy and safety of three different doses of SYHX1901 tablets compared with placebo in the treatment of moderate to severe plaque psoriasis. The total duration of the study will be 20 weeks which will be comprised of: a screening period (4 weeks); an efficacy assessment period (12 weeks) and a follow-up assessment period (4 weeks). Eligible subjects will be randomly assigned to SYHX1901 60 mg qd, 90 mg qd, 180 mg qd or placebo group at a 1:1:1:1 ratio for continuous oral administration for 12 weeks. The presence or absence of treatment with biological agents will be a stratification factor. Subjects will be monitored for the safety throughout the study.

• Study Type: Interventional
• Enrollment (Actual): 93
• Phase: Phase 2

Contacts and Locations

Study Locations

• China
  • Shanghai
    • Shanghai, Shanghai, China
      • Huashan Hospital Affiliated to Fudan University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Subjects fully understand and voluntarily participate in this study and sign informed consent;
2. Age ≥18 and ≤ 75 years old;

3. Subjects with a clinical diagnosis of stable moderate-to-severe plaque psoriasis with a history ≥6 months before randomization; Subjects with stable moderate-to-severe plaque psoriasis defined as meeting all four of the following criteria simultaneously:

   1. Subject must be diagnosed of chronic plaque psoriasis with no morphological changes or significant outbreaks of disease activity assessed by the investigator;
   2. Subject must be a candidate for systemic treatment or phototherapy assessed by the investigator;
   3. Body Surface Area (BSA) affected by plaque-type psoriasis ≥10% at screening and baseline;
   4. PASI score of ≥12 and Physician's Global Assessment (PGA) score ≥3 at screening and baseline;
4. Negative blood pregnancy results should be provided 14 days (inclusive) and 3 days (inclusive) prior to initial dosing, and subjects and their partners should voluntarily take contraceptive measures considered effective by the investigator during the study period and for at least 28 days after the study;
5. Subjects must be volunteer and be able to complete study procedures and follow-up examinations.

Exclusion Criteria:

1. Forms of psoriasis other than plaque psoriasis (Guttate psoriasis、erythrodermic psoriasis、Pustular psoriasis、Drug-induced psoriasis);
2. Previous or current autoimmune disease;
3. Other active skin conditions that may affect the clinical evaluation of psoriasis;
4. Active infection or fever at randomization;
5. Severe bacterial, fungal, or viral infection requiring hospitalization/intravenous drug treatment within 60 days prior to randomization;
6. Any proven history of untreated bacterial infection within 60 days prior to randomization;
7. Any existing evidence of chronic infection;
8. Any proven history of infection of a joint prosthesis or receiving antibiotics for a suspected joint prosthesis infection;
9. Received live vaccine within 60 days before randomization or scheduled to receive live vaccine within 60 days after the end of the study;
10. History of severe herpes zoster or sever herpes simplex infection;
11. Abnormal hepatitis B virus (HBV) related check during screening;
12. Hepatitis C virus (HCV) antibody positive at screening;
13. HIV antibody or treponema pallidum antibody positive;
14. Any known or suspected condition of congenital or acquired immunodeficiency;
15. Tuberculosis (TB);
16. Symptoms or signs of progressive or uncontrolled kidney, liver, blood, gastrointestinal, endocrine, lung, heart, neurological, psychiatric, or brain disease, or with other chronic diseases that the investigator has determined are not suitable for participation in this clinical trial;
17. History of malignancy or lymphoproliferative disease within 5 years (except for cured basal cell carcinoma and in situ cervical cancer);
18. Major surgery within 8 weeks before randomization or surgery planned during the study;
19. Uncontrolled hypertension, systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg after systemic treatment;
20. Having unstable cardiovascular disease defined as presence of a clinical cardiovascular event in the last 3 months or hospitalized for heart disease within the last 3 months; or NYHA≥3 grade, or abnormal ECG suggesting clinically significant and assessed by the investigator as carrying unforeseen risks;
21. History of arterial or venous thrombosis or at high risk;
22. Significant gastrointestinal disorders, such as erosion, hemorrhagic gastroenteritis, a history of bleeding from gastrointestinal ulcers, inflammatory bowel disease, and other disorders that investigator consider to be at risk for gastrointestinal perforation or that may interfere with drug ingestion, transport, or absorption;
23. Uncontrolled hyperlipidemia (TG>2.3 mmol/L and/or LDL>3.4 mmol/L) after standard treatment;
24. Low body weight (weight ≤45 kg or BMI≤18 kg/m^2);
25. BMI ≥30kg/m^2， (severe obesity);
26. Have received local anti-psoriasis therapy within 2 weeks prior to randomization; If topical moisturizers have been used within 2 weeks, they should be continued throughout the trial, with the same frequency and dose until the end of the study;
27. Have used physical therapy within 4 weeks prior to randomization (including photochemotherapy, ultraviolet therapy);

28. Systemic treatments:

    1. Systemic anti-psoriasis therapy within 4 weeks before study drug initiation;
    2. Leflunomide within 6 months before study drug initiation;
    3. Opioid analgesics within 4 weeks before study drug initiation;
    4. Lithium and antimalarial drugs within 4 weeks before study drug initiation;
    5. Any CYP3A4 potent inhibitor/inducer within 4 weeks before study drug initiation;
    6. Any P-gp potent inhibitor/inducer within 4 weeks before study drug initiation;
    7. Thymosin administered by injection or orally within 4 weeks before study drug initiation;
    8. Use of BCRP-sensitive substrate drugs assessed by the investigator during the study;

29. Biological agents:

    1. Exposure to any biological drug directly targeting IL-17 or IL-12, or IL-23 within 6 months prior to randomization ;
    2. Exposure to any TNF monoclonal antibody within 2 months prior to randomization;
    3. Exposure to any monoclonal antibodies against CD20 within 6 months prior to randomization;
    4. Exposure to any T cell or B cell modulators or integrin pathway modulators within 3 months prior to randomization;
    5. Any other biological drugs within 5 half-lives before study drug initiation;
30. Enrolled in a clinical study of any other drug within 3 months or use of any other investigational drugs within 5 half-lives of the investigational treatment before randomization;
31. History of lack of response to treatment after at least 3 months of treatment with any monoclonal antibody targeting IL-17 or IL-23 at approved doses;
32. Organ transplantation (except corneal transplantation more than 3 months before the initiation of the investigational drug);
33. Impossible to avoid prolonged daylight exposure during the trial, or to plan to use UV health rooms or other UV light sources;

34. Laboratory abnormalities of clinical significance assessed by the investigator to pose a risk:

    1. AST or ALT ≥ 2×ULN;
    2. Total bilirubin and/or direct bilirubin >2×ULN;
    3. Neutrophil absolute value (NEUT#) <1.5×10^9/L;
    4. Electrolyte imbalance;
35. History of alcohol and drug abuse or test positive for drug abuse;
36. History of neurological or psychiatric disorders, such as depression, suicidal tendencies, epilepsy, dementia, etc;
37. Any other medical and/or social reasons identified by the investigator as inappropriate for participation in the study;
38. Members of the research team and their immediate families.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Group I (Placebo); Placebo will be administered orally (PO) for 12 weeks.	Drug: Placebo; Administered orally, once daily (QD)
Experimental: Group Ⅱ (SYHX1901 60 mg); SYHX1901 will be administered orally (PO) for 12 weeks.	Drug: SYHX1901; Administered orally, once daily (QD)
Experimental: Group III (SYHX1901 90 mg); SYHX1901 will be administered orally (PO) for 12 weeks.	Drug: SYHX1901; Administered orally, once daily (QD)
Experimental: Group Ⅳ (SYHX1901 180 mg); SYHX1901 will be administered orally (PO) for 12 weeks.	Drug: SYHX1901; Administered orally, once daily (QD)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Percentage of Participants Achieving a Psoriasis Area and Severity Index Score ≥75% (PASI 75) response	Week 12

Secondary Outcome Measures

Outcome Measure	Time Frame
Percentage of Participants Achieving a Psoriasis Area and Severity Index Score ≥50% (PASI 50) response	Week 12
Percentage of Participants Achieving a Physician Global Assessment (PGA) of 0 or 1	Week 12
Change from Baseline in Body Surface Area (BSA) affected with Psoriasis to Week 12	Week 12
Percentage of Participants Achieving a Dermatology Life Quality Index (DLQI) of 0 or 1	Week 12

Other Outcome Measures

Outcome Measure	Time Frame
Incidence of AEs and SAEs	Time Frame:Week 16

Collaborators and Investigators

• Sponsor: CSPC Ouyi Pharmaceutical Co., Ltd.

Study record dates

Study Major Dates

• Study Start (Actual): April 11, 2023
• Primary Completion (Actual): February 21, 2024
• Study Completion (Actual): February 21, 2024

Study Registration Dates

• First Submitted: March 3, 2023
• First Submitted That Met QC Criteria: May 4, 2023
• First Posted (Actual): May 15, 2023

Study Record Updates

• Last Update Posted (Actual): April 30, 2024
• Last Update Submitted That Met QC Criteria: April 29, 2024
• Last Verified: April 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Chemically-Induced Disorders; Skin Diseases; Skin Diseases, Papulosquamous; Psoriasis; Drug-Related Side Effects and Adverse Reactions
• Other Study ID Numbers: SYHX1902-002

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No